CLSD - Clearside Biomedical

-

$undefined

N/A

(N/A)

Clearside Biomedical NasdaqGM:CLSD Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Location: 900 North Point Parkway, Alpharetta, GA, 30005, United States | Website: https://clearsidebio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

101M

Cash

13.63M

Avg Qtr Burn

-5.669M

Short % of Float

0.33%

Insider Ownership

13.02%

Institutional Own.

14.32%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

belzupacap saratalocan (bel-sar) (AU-011) Details
Primary Choroidal Melanoma, Cancer

Phase 3

Data readout

CLS-AX Details
Wet age-related macular degeneration , Age-related macular degeneration

Phase 2b

Data readout

RGX-314 Details
Wet age-related macular degeneration , Age-related macular degeneration

Phase 2

Update

ABBV-RGX-314 Details
Diabetic retinopathy , Diabetic macular edema

Phase 2

Update